In the TME of CRC, high PD-L1 expression is associated with crucial cancer-associated immune responses, including IFN-gamma response, IL-2-STAT5 signaling, and the IL-6-STAT3 signaling pathway. This evidence concerns the gene IL2 and colorectal carcinoma.